128 related articles for article (PubMed ID: 33789449)
1. Genetic variability of
Mutawi TM; Zedan MM; Yahya RS; Zakria MM; El-Sawi MR; Gaedigk A
Pharmacogenomics; 2021 Apr; 22(6):323-334. PubMed ID: 33789449
[No Abstract] [Full Text] [Related]
2. Pharmacogenetics in American Indian populations: analysis of CYP2D6, CYP3A4, CYP3A5, and CYP2C9 in the Confederated Salish and Kootenai Tribes.
Fohner A; Muzquiz LI; Austin MA; Gaedigk A; Gordon A; Thornton T; Rieder MJ; Pershouse MA; Putnam EA; Howlett K; Beatty P; Thummel KE; Woodahl EL
Pharmacogenet Genomics; 2013 Aug; 23(8):403-14. PubMed ID: 23778323
[TBL] [Abstract][Full Text] [Related]
3. Influence of CYP2D6, CYP3A4, CYP3A5 and ABCB1 Polymorphisms on Pharmacokinetics and Safety of Aripiprazole in Healthy Volunteers.
Belmonte C; Ochoa D; Román M; Saiz-Rodríguez M; Wojnicz A; Gómez-Sánchez CI; Martín-Vílchez S; Abad-Santos F
Basic Clin Pharmacol Toxicol; 2018 Jun; 122(6):596-605. PubMed ID: 29325225
[TBL] [Abstract][Full Text] [Related]
4. [CYP2D6, CYP3A5, and CYP3A4 gene polymorphism in Russian, Tatar, and Bashkir populations].
Mustafina OE; Tuktarova IA; Karimov DD; Somova Rs; Nasibullin TR
Genetika; 2015 Jan; 51(1):109-19. PubMed ID: 25857198
[TBL] [Abstract][Full Text] [Related]
5. CYP3A5 but not CYP2D6 polymorphism contributes significantly to the variability in dextropropoxyphene disposition.
Yin OQ; Tomlinson B; Chow MS
J Clin Pharmacol; 2010 Oct; 50(10):1136-41. PubMed ID: 20133509
[TBL] [Abstract][Full Text] [Related]
6. Defining screening panel of functional variants of CYP1A1, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 genes in Serbian population.
Skadrić I; Stojković O
Int J Legal Med; 2020 Mar; 134(2):433-439. PubMed ID: 31858263
[TBL] [Abstract][Full Text] [Related]
7. Genetic polymorphisms of cytochrome P450 enzymes: CYP2C9, CYP2C19, CYP2D6, CYP3A4, and CYP3A5 in the Croatian population.
Ganoci L; Božina T; Mirošević Skvrce N; Lovrić M; Mas P; Božina N
Drug Metab Pers Ther; 2017 Mar; 32(1):11-21. PubMed ID: 28272018
[TBL] [Abstract][Full Text] [Related]
8. Analysis of CYP3A4*1B and CYP3A5*3 polymorphisms in population of Bosnia and Herzegovina.
Semiz S; Dujić T; Ostanek B; Prnjavorac B; Bego T; Malenica M; Mlinar B; Marc J; Causević A
Med Glas (Zenica); 2011 Feb; 8(1):84-9. PubMed ID: 21263403
[TBL] [Abstract][Full Text] [Related]
9. The Influence of the CYP3A4*22 Polymorphism and CYP2D6 Polymorphisms on Serum Concentrations of Aripiprazole, Haloperidol, Pimozide, and Risperidone in Psychiatric Patients.
van der Weide K; van der Weide J
J Clin Psychopharmacol; 2015 Jun; 35(3):228-36. PubMed ID: 25868121
[TBL] [Abstract][Full Text] [Related]
10. Exploring the relationship between expression of cytochrome P450 enzymes and gefitinib pharmacokinetics.
Swaisland HC; Cantarini MV; Fuhr R; Holt A
Clin Pharmacokinet; 2006; 45(6):633-44. PubMed ID: 16719544
[TBL] [Abstract][Full Text] [Related]
11. Influence of genetic variants of CYP2D6, CYP2C9, CYP2C19 and CYP3A4 on antiepileptic drug metabolism in pediatric patients with refractory epilepsy.
López-García MA; Feria-Romero IA; Serrano H; Rayo-Mares D; Fagiolino P; Vázquez M; Escamilla-Núñez C; Grijalva I; Escalante-Santiago D; Orozco-Suarez S
Pharmacol Rep; 2017 Jun; 69(3):504-511. PubMed ID: 28343093
[TBL] [Abstract][Full Text] [Related]
12. Association Between the Lower Extremity Deep Venous Thrombosis, the Warfarin Maintenance Dose, and CYP2C9*3, CYP2D6*10, and CYP3A5*3 Genetic Polymorphisms: A Case-Control Study.
Ju S; Gao Y; Cao X; Zhang XF; Yan CC; Liu FT
Genet Test Mol Biomarkers; 2017 Sep; 21(9):539-546. PubMed ID: 28872889
[TBL] [Abstract][Full Text] [Related]
13. Pharmacogenetic relevant polymorphisms of CYP2C9, CYP2C19, CYP2D6, and CYP3A5 in Bhutanese population.
Dorji PW; Wangchuk S; Boonprasert K; Tarasuk M; Na-Bangchang K
Drug Metab Pers Ther; 2019 Dec; 34(4):. PubMed ID: 32004143
[TBL] [Abstract][Full Text] [Related]
14. Genetic polymorphisms of cytochrome P450 among patients with Balkan endemic nephropathy (BEN).
Atanasova SY; von Ahsen N; Toncheva DI; Dimitrov TG; Oellerich M; Armstrong VW
Clin Biochem; 2005 Mar; 38(3):223-8. PubMed ID: 15708542
[TBL] [Abstract][Full Text] [Related]
15. Naturalistic pharmacogenetic study of treatment resistance to typical neuroleptics in European-Brazilian schizophrenics.
Kohlrausch FB; Gama CS; Lobato MI; Belmonte-de-Abreu P; Callegari-Jacques SM; Gesteira A; Barros F; Carracedo A; Hutz MH
Pharmacogenet Genomics; 2008 Jul; 18(7):599-609. PubMed ID: 18551040
[TBL] [Abstract][Full Text] [Related]
16. CYP3A4 and CYP3A5 genotyping by Pyrosequencing.
Garsa AA; McLeod HL; Marsh S
BMC Med Genet; 2005 May; 6():19. PubMed ID: 15882469
[TBL] [Abstract][Full Text] [Related]
17. Effects of CYP3A5 and CYP2D6 genetic polymorphism on the pharmacokinetics of diltiazem and its metabolites in Chinese subjects.
Zheng T; Su CH; Zhao J; Zhang XJ; Zhang TY; Zhang LR; Kan QC; Zhang SJ
Pharmazie; 2013 Apr; 68(4):257-60. PubMed ID: 23700791
[TBL] [Abstract][Full Text] [Related]
18. Lack of Influence by CYP3A4 and CYP3A5 Genotypes on Pain Relief by Hydrocodone in Postoperative Cesarean Section Pain Management.
Hosseinnejad K; Yin T; Gaskins JT; Stauble ME; Wu Y; Jannetto P; Langman LL; Jortani SA
J Appl Lab Med; 2019 May; 3(6):954-964. PubMed ID: 31639687
[TBL] [Abstract][Full Text] [Related]
19. Effect of CYP3A4*22, CYP3A5*3, and CYP3A combined genotypes on tamoxifen metabolism.
Sanchez Spitman AB; Moes DJAR; Gelderblom H; Dezentje VO; Swen JJ; Guchelaar HJ
Eur J Clin Pharmacol; 2017 Dec; 73(12):1589-1598. PubMed ID: 28849250
[TBL] [Abstract][Full Text] [Related]
20. Allele and genotype frequencies of the polymorphic cytochrome P450 genes (CYP1A1, CYP3A4, CYP3A5, CYP2C9 and CYP2C19) in the Jordanian population.
Yousef AM; Bulatova NR; Newman W; Hakooz N; Ismail S; Qusa H; Zahran F; Anwar Ababneh N; Hasan F; Zaloom I; Khayat G; Al-Zmili R; Naffa R; Al-Diab O
Mol Biol Rep; 2012 Oct; 39(10):9423-33. PubMed ID: 22722998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]